Carriers of a pathogenic BAP1 mutation are at high risk for the development of benign BAP1-inactivated melanocytic tumors and various cancers, including mesothelioma, uveal and cutaneous melanomas, renal cell cancer, basal cell carcinoma, meningioma, and cholangiocarcinoma [1,2]. This evidence concerns the gene BAP1 and cutaneous melanoma.